This report examines the historical trajectory of vaccine development in the United States and the subsequent emergence of messenger RNA (mRNA) technology as a critical tool for disease mitigation.

本報告探討美國疫苗發展的歷史軌跡，以及隨後出現的信使核糖核酸（mRNA）技術如何成為緩解疾病的關鍵工具。

The historical implementation of vaccines has facilitated the systemic reduction or eradication of numerous high-mortality pathogens. Initial advancements, such as the 1796 smallpox vaccine, established a precedent for public health interventions, eventually leading to the global eradication of the variola virus. Subsequent developments in the early 20th century targeted bacterial infections, including diphtheria, tetanus, and pertussis, while the mid-century witnessed the introduction of vaccines for polio, influenza, and various childhood viral infections. These interventions transitioned several previously endemic diseases, such as measles and rubella, to eliminated status within the United States by the early 21st century.

疫苗的歷史實施促進了系統性地減少或根除許多高死亡率的病原體。最初的進展，例如 1796 年的天花疫苗，為公共衛生干預建立了先例，最終導致天花病毒在全球被根除。20 世紀初的後續發展針對細菌感染，包括白喉、破傷風和百日咳，而世紀中期則見證了小兒麻痺、流感和各種兒童病毒感染疫苗的推出。這些干預措施使幾種此前為地方性流行的疾病（如麻疹和德國麻疹）在 21 世紀初之前在美國達到消滅狀態。

Contemporary medical advancements have introduced the mRNA platform, which utilizes synthetic genetic instructions to induce an immune response without altering the host genome. A review published in The Lancet indicates that this platform is safe and efficacious, noting that the risk of vaccine-associated myocarditis is significantly lower than the risk posed by COVID-19 infection. Furthermore, the transition from permanently cationic to ionisable lipids has enhanced the safety profile of these delivery systems. While the platform demonstrates high efficacy in preventing severe illness and hospitalization, its inability to provide robust mucosal immunity in the upper respiratory tract necessitates the use of booster doses to maintain protection against infection.

當代醫學進步引入了 mRNA 平台，該平台利用合成的遺傳指令來誘導免疫反應，而不會改變宿主基因組。發表在《刺胳針》（The Lancet）的一篇評論指出，該平台是安全且有效的，並提到疫苗相關心肌炎的風險顯著低於 COVID-19 感染所帶來的風險。此外，從永久陽離子轉向可電離脂質，提升了這些遞送系統的安全概況。雖然該平台在預防重症和住院方面表現出高療效，但由於其無法在上呼吸道提供強大的黏膜免疫，因此需要使用加強劑以維持對感染的保護。

Despite these clinical successes, the institutionalization of vaccination faces significant headwinds. Data from UNICEF and social media sentiment analyses indicate a decline in vaccine confidence across a majority of nations. This erosion of trust is attributed to the proliferation of misinformation and the politicization of medical discourse. Consequently, there is a documented risk of a resurgence in vaccine-preventable diseases if population coverage falls below critical thresholds, such as the 95% requirement for measles prevention. Future applications of mRNA technology are currently being explored in oncology and gene therapy to address genetic deficiencies and malignant mutations.

儘管有這些臨床成功，但疫苗接種的制度化面臨著顯著的阻力。來自聯合國兒童基金會（UNICEF）的數據和社交媒體情緒分析顯示，大多數國家的疫苗信心有所下降。這種信任的侵蝕歸因於錯誤資訊的泛濫和醫療論述的政治化。因此，已有記錄顯示，如果人群覆蓋率低於臨界閾值（例如預防麻疹所需的 95%），疫苗可預防疾病可能會再次爆發。目前正在腫瘤學和基因治療中探索 mRNA 技術的未來應用，以解決遺傳缺陷和惡性突變。

Vaccination remains a primary instrument of public health, though its continued efficacy is contingent upon the resolution of systemic vaccine hesitancy and ongoing technological refinement.

疫苗接種仍然是公共衛生的主要工具，儘管其持續效力取決於系統性疫苗猶豫的解決以及持續的技術改良。